Blavatnik Fellowship in Life Science Entrepreneurship

The Blavatnik Fellowship in Life Science Entrepreneurship offers Harvard Business School alumni and Harvard-affiliated postdocs the opportunity to create new ventures around promising life-science technologies while developing their leadership talents.
Supporting Blavatnik Fellows in their pursuit of successful enterprise creation, the program provides practical materials for entrepreneurship—time, working space, operating funds—with access to strategic resources—mentorship, workshops, and fireside chats, with industry experts.
The Blavatnik Fellowship is led by faculty chair Peter Barrett, PhD. The members of the Key Advisory Board, leading industry and biomedical authorities, provide programmatic guidance as well as one-on-one mentorship to Blavatnik Fellows. The Blavatnik Entrepreneurship Network, a consortium of top business and science leaders, provides Fellows additional mentorship channels.
Ideal candidates are MBA alumni of Harvard Business School who have graduated within the last 7–10 years, or post-doctoral candidates within the first 5 years of their training program at a Harvard program or research lab. The program is a full-time, salaried, residential fellowship. As such, Blavatnik Fellows are expected to reside in the Boston area, are eligible to enroll in a range of Harvard employee benefits, and receive work space at the Pagliuca Harvard Life Lab.
How to apply
For complete information, visit the HBS Blavatnik Fellowship webpage or email Tracy Saxton Perry, Assistant Director.
Five Years of Thinking Big
By bringing together expertise and experience from across Harvard, the Accelerator and the HBS Fellows program will further enhance Harvard’s commitment to innovative research and entrepreneurship.
Dean Nitin Nohria
Harvard Business School
2020–21 Fellows
|
|
|
|
|
Faculty Chair
In addition to his work at Harvard, Peter is a Partner at Atlas Venture, an early stage life science venture capital firm. Since 2002, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Prior to Atlas he was co-founder, executive vice president, and chief business officer of Celera Genomics, and held senior management positions at Applera. Peter is currently chairman of Obsidian Therapeutics, Zafgen, Cadent Therapeutics, and Synlogic and sits on the boards of Indalo and Perkin Elmer. Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Program for Management Development. |